Shareholder Alert: The Ademi Firm investigates whether VYNE Therapeutics Inc. is obtaining a Fair Price for its Public Shareholders

Core Viewpoint - The Ademi Firm is investigating VYNE for potential breaches of fiduciary duty and legal violations related to its transaction with Yarrow Bioscience [1] Transaction Details - In the transaction, pre-Merger VYNE shareholders are expected to own approximately 3% of the combined company, while pre-Merger Yarrow shareholders are expected to own approximately 97% [2] - VYNE insiders are set to receive substantial benefits as part of change of control arrangements [2] Board Conduct Investigation - The transaction agreement imposes significant penalties on VYNE for accepting competing bids, which may limit competing transactions unreasonably [3] - The investigation focuses on whether the VYNE board of directors is fulfilling their fiduciary duties to all shareholders [3]